FRIENDSWOOD, Texas — November 11, 2025 — Leads & Copy — Castle Biosciences, Inc. (Nasdaq: CSTL) will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, Dec. 2, 2025, at 1:10 p.m. Eastern time.
The presentation will be accessible via a live audio webcast on the Castle Biosciences website. A replay of the webcast will be available after the live broadcast concludes.
Castle Biosciences (Nasdaq: CSTL) focuses on innovative tests that guide patient care. Primarily focused on dermatologic and gastroenterological diseases, the company develops personalized, clinically actionable solutions. These tests aim to improve disease management and patient outcomes.
Castle Biosciences prioritizes patients and clinicians, providing support for confident treatment planning through advanced molecular tests and rigorous science. The company’s trademarks include DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, DecisionDx-UM, DecisionDx-PRAME, and DecisionDx-UMSeq.
Investor Contact: Camilla Zuckero, czuckero@castlebiosciences.com
Media Contact: Allison Marshall, amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
